Minerva Neurosciences reported $2.84M in Selling and Administration Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US USD 78.11M 11.79M
Adma Biologics ADMA:US USD 17.75M 1.86M
ALKERMES ALKS:US USD 152.78M 2.4M
AstraZeneca AZN:LN USD 3.35B 280M
Biocryst Pharmaceuticals BCRX:US USD 36.92M 1.1M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Dynavax Technologies DVAX:US USD 32.04M 3.69M
Eli Lilly And LLY:US USD 1.61B 10.9M
Esperion Therapeutics ESPR:US USD 24.95M 4.65M
Halozyme Therapeutics HALO:US USD 34.07M 23.41M
IONIS PHARMACEUT IONS:US USD 34.42M 614K
Johnson & Johnson JNJ:US USD 6.51B 423M
Marinus Pharmaceuticals MRNS:US USD 13.39M 3.67M
Merk MRK:US USD 2.49B 9M
Minerva Neurosciences NERV:US USD 2.84M 6.57K
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Novartis NOVN:VX USD 3.4B 185M
Novavax NVAX:US USD 122.88M 14.72M
Pfizer PFE:US USD 4.87B 1.33B
Roche Holding ROG:VX 5.64B 899M
Takeda 4502:JP JPY 248.73B 17.25B
Vanda Pharmaceuticals VNDA:US USD 59.71M 26.71M